Context Therapeutics to Participate in Upcoming Investor Conferences

February 9, 2026

PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its participation in several upcoming investor conferences.

Upcoming Investor Conferences

- Guggenheim Emerging Outlook: Biotech Summit 2026, February 11-12, 2026, New York, NY
  Fireside Chat: Wednesday, February 11th at 8:30 AM ET
  1x1 Meetings on February 11th
- TD Cowen 46th Annual Health Care Conference, March 2-4, 2026, Boston, MA
  Presentation: Tuesday, March 3rd at 10:30 AM ET*
  1x1 Meetings on March 3rd
- Citizens Life Sciences Conference, March 10-11, 2026, Miami, FL
  Fireside Chat: Tuesday, March 10th at 11:20 AM ET
  1x1 Meetings on March 10th
- Leerink Partners Global Healthcare Conference, March 8-11, 2026, Miami, FL
  Fireside Chat: Wednesday, March 11th at 9:20 AM ET*
  1x1 Meetings on March 11th

*A live webcast of the presentation will be available on the News and Events section of the Company’s website at https://ir.contexttherapeutics.com. Replays will be available on the website for 90 days.

For additional information or to request a meeting with members of Context’s management team during these events, please contact your conference representative or IR@contexttherapeutics.com.

About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context’s goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.

Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the Company and its employees to participate in and present at conferences, (ii) the potential benefits, characteristics, safety and side effect profile of our product candidates, and (iii) the likelihood data will support future development. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

Investor Relations Contact:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics
IR@contexttherapeutics.com